et al., Biomedicines, doi:10.3390/biomedicines9050509 (preprint 4/6/21) (Peer Reviewed)
Retrospective study of calcitriol supplementation with chronic kidney disease patients in Catalonia showing lower cases, severe cases, and mortality with supplementation. A dose-response relationship was found for severe cases and mortality.
Oristrell et al., 4/6/2021, retrospective, Spain, Europe, peer-reviewed, 10 authors, dosage calcifediol 0.3mg daily, mean daily dose.
risk of death, 43.0% lower, RR 0.57, p = 0.001, treatment 2296, control 3407, multivariate, patients with CKD stages 4-5.
risk of COVID-19 severe case, 43.0% lower, RR 0.57, p < 0.001, treatment 2296, control 3407, multivariate, patients with CKD stages 4-5.
risk of COVID-19 case, 22.0% lower, RR 0.78, p = 0.01, treatment 163 of 2296 (7.1%), control 326 of 3407 (9.6%), multivariate, patients with CKD stages 4-5.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.